The hypercholesterolemia market is expected to grow in the coming years due to an increase in the prevalent cases of hypercholesterolemia, along with the expected launch of emerging therapies. LAS VEGAS , May 23, 2024 /PRNewswire/ -- DelveInsight's Hypercholesterolemia Market Insights report includes a comprehensive understanding of current treatment practices, hypercholesterolemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ) and the United Kingdom , and Japan ]. Key Takeaways from the Hypercholesterolemia Market Report According to DelveInsight's analysis, the market size for hypercholesterolemia is expected to grow significantly by 2034.
As per DelveInsight's estimates, the prevalence of hypercholesterolemia in the US indicates that it is most commonly observed in the age group ranging from 45 to 64 , suggesting a higher prevalence among the older population. Leading hypercholesterolemia companies such as Novartis Pharmaceuticals, Merck Sharp & Dohme LLC, Esperion Therapeutics, Inc., Arrowhead Pharmaceuticals, LIB Therapeutics LLC, Medpace, Inc.
, AstraZeneca, NewAmsterdam Pharma , and others are developing novel hypercholesterolemia drugs that can be available in the hypercholesterolemia market in the coming years. The promising hypercholesterolemia therapies in the pipeline include Inclisiran, MK-0616, Bempedoic acid, .
